Real-World Outcomes in the Evolving Second-Line Systemic Therapy Landscape in Hepatocellular Carcinoma: A Single-Institution Experience.
OBJECTIVES Historically, few treatments existed for hepatocellular carcinoma (HCC) until sorafenib's approval in 2007. Meaningful treatment advances included approval of atezolizumab plus bevacizumab in 2020 and tremelimumab plus durvalumab in 2022. However, optimal second-line systemic therapy and outcomes after curre...